Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry
Analytical Chemistry · 21.03.2023 · 95 (11) · 4834-4839
DOI: 10.1021/acs.analchem.2c04417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, online erschienen am 06.03.2023. Verfasst von John C Tran und 24 weiteren Autor:innen. Beteiligte Einrichtung: CellCarta, Montreal, Quebec H2X 3Y7, Canada. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
The growing opportunities recognized for covalent drug inhibitors, like KRAS G12C inhibitors, are driving the need for mass spectrometry methods that can quickly and robustly measure therapeutic drug activity in vivo for drug discovery research and development. Effective front-end sample preparation is critical for proteins extracted from tumors but is generally labor intensive and impractical for large sample numbers typical in pharmacodynamic (PD) studies. Herein, we describe an automated and integrated sample preparation method for the measurement of activity levels of KRAS G12C drug inhibitor alkylation from complex tumor samples involving high throughput detergent removal and preconcentration followed by quantitation using mass spectrometry. We introduce a robust assay with an average intra-assay coefficient of variation (CV) of 4% and an interassay CV of 6% obtained from seven studies, enabling us to understand the relationship between KRAS G12C target occupancy and the therapeutic PD effect from mouse tumor samples. Further, the data demonstrated that the drug candidate GDC-6036, a KRAS G12C covalent inhibitor, shows dose-dependent target inhibition (KRAS G12C alkylation) and MAPK pathway inhibition, which correlate with high antitumor potency in the MIA PaCa-2 pancreatic xenograft model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CellCarta, Montreal, Quebec H2X 3Y7, Canada.
ORCID-Profile: John C Tran, Hans E Purkey
Zitieren
APA
Tran, J. C., Hunsaker, T., Bell, C., Ma, T. P., Chan, E., Larrocha, P. S., Homyk, K., Liu, L., La, H., Mao, J., de la Cruz, C. C., Yu, K., Beresini, M., Forrest, W. F., Xiao, Y., Jang, A., Samus, N., Stesco, N. D., Mentinova, M., …, & Merchant, M. (2023). Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry. Analytical Chemistry, 95(11), 4834-4839. https://doi.org/10.1021/acs.analchem.2c04417
Vancouver
Tran JC, Hunsaker T, Bell C, Ma TP, Chan E, Larrocha PS, et al. Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry. Analytical Chemistry. 2023;95(11):4834-4839. doi:10.1021/acs.analchem.2c04417
BibTeX
@article{Tran2023,
author = {Tran, John C and Hunsaker, Thomas and Bell, Christina and Ma, Taylur P and Chan, Emily and Larrocha, Pablo Saenz-Lopez and Homyk, Kelsey and Liu, Liling and La, Hank and Mao, Jialin and de la Cruz, Cecile C and Yu, Kebing and Beresini, Maureen and Forrest, William F and Xiao, Yang and Jang, Anne and Samus, Natalia and Stesco, Nicholas Dupuis and Mentinova, Marija and Parent, Stephane and Pottiez, Gwenael and Schirm, Michael and Purkey, Hans E and Liu, Yichin and Merchant, Mark},
title = {Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry},
journal = {Analytical Chemistry},
year = {2023},
volume = {95},
number = {11},
pages = {4834--4839},
doi = {10.1021/acs.analchem.2c04417}
}
EUVIMED